ARDXArdelyx, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 11866
Ticker: ARDX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2014-06-19
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ARDX

Detail

Enriched 2026-08-14 20:47

Market cap: $1,025,004,660.84
Shares outstanding (class): 249,187,572
Shares outstanding (weighted): 258,187,572
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 489
Location: FREMONT, CA
Homepage: https://www.ardelyx.com
Description: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Market cap and share counts drift.

Funds holding this security

83 funds · 83 positions · $224.07M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$45.91M	0.62%	7,664,448 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$44.36M	0.00%	7,404,867 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$35.09M	0.05%	5,857,352 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$16.19M	0.02%	2,702,696 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$15.55M	0.30%	2,595,821 NS	FIGI
College Retirement Equities Fund - Total Global… College Retirement Equities Fund	—	$12.21M	0.01%	2,037,579 NS	FIGI
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$12.08M	0.12%	2,016,043 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$11.74M	0.10%	1,959,561 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$3.68M	0.15%	613,718 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$2.40M	0.05%	400,907 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.80M	0.00%	300,929 NS	FIGI
SMALL COMPANY GROWTH PORTFOLIO VANGUARD VARIABLE INSURANCE FUNDS	—	$1.56M	0.11%	259,834 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$1.50M	0.04%	250,341 NS	FIGI
VANGUARD MARKET NEUTRAL FUND VANGUARD MONTGOMERY FUNDS	—	$1.34M	0.31%	223,904 NS	FIGI
BlackRock Advantage Small Cap Growth Fund BlackRock Funds	—	$1.23M	0.18%	204,920 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERARDX
FIGI_COMPOSITEBBG001WH4DQ3
FIGI_SHARE_CLASSBBG001WH4F33
CIK0001437402
ISINUS0396971071
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Ardelyx is a biopharmaceutical company focused on developing treatments for kidney and gastrointestinal diseases, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.